Document:

Exhibit 10.1

 

AGREEMENT FOR THE
PURCHASE AND SALE OF LIMITED LIABILITY COMPANY INTERESTS OF GENRESULTS, LLC

 

This Agreement
for the Purchase and Sale of Limited Liability Company Interests ("Agreement") is made as of April 12, 2019, between
David G. Jemmett and Jemmett Enterprises, LLC, an Arizona limited liability company (collectively, the "Seller")
and Cerberus Cyber Sentinel Corporation, a Delaware corporation (the "Purchaser”).

 

WHEREAS,
Seller is the owner of 100% of the legal and beneficial equity interests (the “Equity Interests”) in GenResults,
LLC, an Arizona limited liability company (the "Company");

 

WHEREAS,
Seller desires to sell and Purchaser desires to purchase the Equity Interests, currently owned by
Seller.

 

NOW, THEREFORE, the
parties hereto agree as follows: Section 1.Purchase and Sale.

1.1              
Pursuant to the terms and conditions of this Agreement, Seller hereby agrees to sell to Purchaser,
and Purchaser hereby agrees to purchase from Seller, the Equity Interests.

 

1.2              
In consideration of the Equity Interests at the Closing Purchaser shall issue to Seller One
Million (1,000,000) shares of Purchaser’s common stock (the "Purchase Price").

 

Section 2.Closing.

 

2.1              
The closing shall take place, subject to the conditions set forth in Section 2.2 hereof
at 10:00 A.M. on April 12, 2019 (“Closing”), at the offices of the Company or such other time or place as the
parties hereto may mutually agree.

 

2.2              
All profits and liabilities of Seller through and including close of business on the Effective
Date (as hereinafter defined) shall accrue to Seller, and thereafter shall be for the account of Purchaser. All prorations to be
made hereunder will be made as of the close of business on the Effective Date.

 

2.2              
The obligation of the Seller to sell the Equity Interests, and the obligation of the Purchaser
to purchase the Equity Interests, is subject to the conditions set forth below being complied with to the satisfaction of, or waived
by, the Seller or the Purchaser, as the case may be, on or before the Closing.

 

2.2.1                     
Delivery of Equity Interests.The Seller shall deliver to Purchaser evidence satisfactory
to Purchaser transferring the Equity Interests to Purchaser.

 

2.2.2                     
Delivery of Purchase Price. The Seller shall have received the Purchase Price, as evidenced
by stock certificates or ledger entry.

    	1 

    	 

    

2.2.3                     
Representations of Warranties. The representations and warranties of Seller contained
in this Agreement shall be true and correct as of the Closing.

 

2.2.4                     
Purchasers Representations and Warranties. The representations and warranties of the
Purchaser contained in this Agreement shall be true and correct as of the Closing.

 

Section 3.Seller’s Representations and Warranties.

 

Seller represents and warrants to Purchaser that:

 

3.1                              
Organization, Good Standing, etc. The Company is a limited liability company duly organized
and validly existing and in good standing under the laws of the State of Arizona and is duly qualified to do business, and is in
good standing, in every jurisdiction in which the nature of its business requires it to be so qualified. The Company has all requisite
corporate power and authority to carry on its business as now conducted. The equity interests in the Company are not now, and have
never been, certificated.

 

3.2                              
No Conflict. The execution, delivery and performance by the Seller of this Agreement
will not conflict with or result in the breach of or constitute a default under any other agreement or instrument to which the
Company is a part of which it or its property may be bound, or result in the creation of any lien thereunder.

 

3.3                              
Authorization. This Agreement has been duly authorized, executed and delivered by the
Seller.

 

3.4                              
No Violation. The execution, delivery or performance by the Seller of this Agreement
does not contravene any law, regulation, order or judgment applicable to or binding on the Seller, and will not result in a breach
of, or constitute a default under, or contravene any provisions of, any agreement to which the Seller is a party or by which he
is bound.

 

3.5                              
No Consents or Approvals. Neither the execution, delivery or performance by the Seller
of this Agreement requires the consent or approval of, the giving of notice to, the registration with, the recording or filing
of any documents with, or the taking of any other action in respect of, any federal, state or local governmental commission, authority,
agency or body.

 

3.6                              
Equity Interests. Seller is the lawful owner, of record and beneficially, of the Equity
Interests and has good and merchantable title thereto, free and clear of all liens, encumbrances, options, charges, equities and
claims of any kind whatsoever, and he has full right and legal capacity to transfer and sell the Equity Interests to the Purchaser
under the terms and conditions contained herein and that upon Closing under this Agreement the Equity Interests the Purchaser will
own legal and equitable title to the Equity Interests, free and clear of all liens, encumbrances, charges options, equities and
claims of any kind. The Equity Interests represent all of the issued and outstanding equity interests of the Company.

 

3.7                              
Financial Statements. The Company’s unaudited financial statements as of December
31, 2018, and the Company’s unaudited financial statements for the period ending March 31, 2019 (the “Effective
Date”), which have been delivered to Purchaser, have been prepared by Seller’s

    	2 

    	 

    

management in accordance with
generally accepted accounting principles applied on a consistent basis and fairly present the financial condition of the Company
as at such date and the result of its operations and the changes in financial position for the period then ended. There have been
no material adverse changes in the condition or operations, financial or otherwise, of the Company since March 31, 2019. The net
equity value of the Company, as reflected on the Company’s financial statements, as of the Effective Date is $10,000.

 

3.8                              
Tax Returns. All appropriate federal, state and local income tax returns which are
required to have been filed for all of the Company’s taxable periods either have been filed or timely extensions obtained.
All taxes as shown on said returns have been paid when due. The Seller knows of no proposed material tax assessment against the
Company, or of any penalty, charge, or amounts owning to taxing authorities by the Company.

 

3.9                              
Litigation. There are no actions, suits or proceedings pending or, to the knowledge
of the Seller, threatened against or affecting the Company, at law or in equity, or before any governmental board, agency or instrumentality
or any arbitrator. The Company is not in default with respect to any material order, writ, injunction or decree of any court or
governmental board, agency or other instrumentality.

 

3.10                       
Accuracy of Information Provided to Purchaser. No written information, exhibit, financial
statement, document, book, record or report prepared by the Company or Seller, which has been, is or to be furnished by the Company
or Seller to Purchaser in connection with the transactions described in this Agreement is or shall be inaccurate in any material
respect as of the date it is or shall be dated or (except as otherwise disclosed to Purchaser) at such time as of the date so furnished,
or contains or shall contain any material misstatement of fact.

 

3.11                       
Licenses. The Company possesses all licenses, permits, franchises, patents, copyrights,
trademarks, and trade names, or rights thereto, necessary to conduct its business substantially as now conducted and as presently
proposed to be conducted, and the Company is not in violation of any valid rights of others with respect to any of the foregoing.

 

3.12                       
ERISA. The Company is in compliance in all material respects with all laws, rules,
regulations and orders of any governmental authority, including without limitation the Employee Retirement Income Security Act
of 1974 ("ERISA") to the extent applicable to it and has received no notice to the contrary from the Pension Benefit
Guaranty Corporation ("PBGC") or any other governmental entity, authority or agency.

 

3.13                       
Material Liability. There are no liabilities of the Company, fixed or contingent, which
are material but are not reflected in the financial statements or in the notes thereto, other than liabilities arising in the ordinary
course of business since March 31, 2019.

 

3.14                       
Other Agreements. The Company is not a party to any indenture, loan, or credit agreement,
or to any lease or other agreement or instrument, or subject to any charter or corporate restriction which could have a material
adverse effect on the business, properties, assets, operations, or conditions, financial or otherwise, of the Company. The Company
is not in default in any material respect in the performance, observance, or fulfillment of any of the obligations, covenants,
or conditions contained in any agreement or instrument to which it is a party.

    	3 

    	 

    

3.15                       
Ownership and Liens. The Company has title to, or valid leasehold interests in, all
of its properties and assets, real and personal, including the properties and assets and leasehold interest reflected in the financial
statements referred to in Section 3.7 (other than any properties or assets disposed of in the ordinary course of business), and
none of the properties and assets owned by the Company and none of its leasehold interests are subject to any lien, mortgage, pledge,
security interest, or other charge or encumbrance of any kind.

 

Section 4.Purchaser’s Representation and Warranties.

 

The Purchaser represents and warrants to the Seller that:

 

4.1.                           
No Violation. The execution, delivery or performance by
the Purchaser of this Agreement does not contravene any law, regulation order or judgment applicable to or binding on the Purchaser
and will not result in a breach of, or constitute a default, or contravene any provision of, any agreement to which Purchaser is
a party or by which he is bound.

 

4.2.                           
No Consents or Approvals. Neither the execution, delivery or performance by the Purchaser
of this Agreement requires the consent or approval of, the giving of notice to, the registration with, the recording or filing
of any documents with, or the taking of any other action in respect of, any federal, state or local governmental commission, authority,
agency or body.

 

4.3.                           
Securities Laws. The Purchaser acknowledges and agrees that the Equity Interests have
not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and applicable state
securities laws, and that the transfer of the Equity Interests may be effected only pursuant to an effective registration under
the Securities Act and applicable state securities laws or an exemption therefore. The Purchaser is acquiring the Equity Interests
for his own account for the purpose of investment only and not with a present intention to transfer, hypothecate, resell or otherwise
distribute such Shares within the meaning of the Securities Act and applicable state securities laws.

 

4.4                           
Access to Data. The Purchaser has received and reviewed information about the Company and
has had an opportunity to discuss the Company’s business, management and financial affairs with its management and to review the
Company’s facilities.

 

Section 5. Indemnification.

 

5.1                           
By Seller. All representations,
warranties, covenants and agreements of the Seller contained herein, or in any agreement, certificate or document executed by any
Seller in connection herewith and all indemnification obligations set forth in this Section 5.1, will survive the Closing
for a period of three (3) years from the Closing. Any claims made under this Section 5.1 will be made or asserted by Purchaser
to Seller in writing within three (3) years from the Closing. Notwithstanding the above, any claim made for a breach of any representation,
warranty, covenant or agreement of Seller contained in this Agreement relating to tax matters, or any liability for taxes, may
be made until the expiration of the applicable statute of limitations (including any extension thereof) governing claims by the
applicable governmental authority or person with respect to such matters. The Seller, jointly and severally, agree to indemnify,
defend and hold harmless Purchaser and/or the Purchaser's assignee and their respective stockholders, officers, directors, members,
managers, partners, employees, agents, successors and assignees (collectively, the "Purchaser Indemnitees"),
from and against any and all

    	4 

    	 

    

losses, damages, liabilities,
obligations, assessments, suits, actions, proceedings, claims or demands, including costs, expenses and fees (including reasonable
attorneys' fees, accountant, paralegal, and expert witness fees) incurred in connection with, suffered by any of them or asserted
against any of them or the assets acquired by Purchaser hereunder (collectively, "Purchaser's Losses"),
arising out of or based upon (a) the failure of any representation or warranty of Seller contained herein, or in any agreement,
certificate or document executed by Seller in connection herewith, to be true and correct in all material respects when made, (b)
the breach in any material respect of any material covenant or agreement of Seller contained in this Agreement, (c) any liability
or obligation of Seller arising out of Seller's Business prior to the Effective Date, or (d) any arrangements or agreements made
or alleged to have been made by Seller with any broker, finder or other agent in connection with the transactions contemplated
hereby.

 

Section 6. Further Assurances.

 

6.1.                            
By Seller. Seller will do, execute, acknowledge and deliver, or shall cause to be done,
executed, acknowledged and delivered all such further acts, conveyances and assurances the Purchaser may reasonably require for
accomplishment of the purposes of this Agreement.

 

6.2.                            
By Purchaser. The Purchaser will do, execute, acknowledge and deliver, or shall cause
to be done, executed, acknowledged and delivered, all such further acts, conveyances and assurances as Seller may reasonably require
for accomplishment of the purposes of this Agreement.

 

Section 7. Miscellaneous.

 

7.1.                            
Counterparts. This Agreement may be executed by the parties hereto in separate counterparts,
each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute but one
and the same instrument.

 

7.2.                            
Amendment. Neither this Agreement nor any of the terms hereof may be terminated, amended,
supplemented, waived or modified orally, but only by an instrument in writing which purports to terminate, amend, supplement, waive
or modify this Agreement or any of the terms hereof and is signed by the party against which the enforcement of the termination,
amendment, supplement, waiver or modification is sought.

 

7.3.                            
Successors and Assigns. The terms of this Agreement shall be binding on, and inure
to the benefit of, the parties hereto and their respective successors and assigns.

 

7.4.                            
Governing Law. This Agreement, including all matters of construction, validity and
performance, shall in all respects be governed by, and construed in accordance with, the laws of the State of Arizona.

 

7.5.                            
Notices. Except as otherwise provided in this Agreement, all notices hereunder shall
be in writing and shall be given by mail, personal delivery, overnight courier, telecopy or any other customary means of written
communication at the addresses set forth on the signature pages hereof, or at such other addresses as may be specified by written
notice to the parties hereto, and shall become effective when received by the addressees.

    	5 

    	 

    

7.6.                            
Severability of Provisions. Any provision of this Agreement which is prohibited or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
without invalidating the remaining provisions hereof or affecting the validity or enforceable of such provision in any other jurisdiction.

 

7.7.                            
Headings. The headings used herein are for convenience of reference only and shall
not define or limit any of the terms or provisions hereof.

 

7.8.                            
Entire Agreement. This Agreement embodies the entire agreement and understanding between
the parties hereto and supersedes all prior agreements and understandings between the parties hereto relating to the subject matter
hereof.

 

 

[Remainder of Page Intentionally Left Blank]

    	6 

    	 

    

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers
thereunto duly authorized as of the date and year first above written.

 

	SELLER:	PURCHASER:
	
        Jemmett Enterprises, LLC,

        an Arizona limited liability company
	Cerberus Cyber Sentinel Corporation, a Delaware corporation
	By: /s/
    David G Jemmett	By: /s/
    David G. Jemmett
	Name: David G Jemmett	Name: David G Jemmett
	Title:Managing Partner	Title:C.E.O.
	
         /s/ David G. Jemmett

        David G. Jemmett
	 
	
         

        SELLER ADDRESS:
	
         

        PURCHASER ADDRESS:

	
         

        2700 N Central Ave # 900

        Phoenix, Arizona 85004
	
         

        2700 N Central Ave # 900

        Phoenix, Arizona 85004Exhibit
10.10

 

COLLABORATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

THIS
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of this 10th
day of September (the “Effective Date”), by and between INFINITE MIND LLC (“IM”),
a Florida limited liability company having a place of business at 3259 Progress Drive, Suite 107, Orlando, Florida 32826 and
AVRA MEDICAL ROBOTICS, INC. (“AVRA”), a Florida corporation having a place of business at 3259
Progress Drive, Suite 114, Orlando, Florida 32826

 

RECITALS

 

WHEREAS,
IM is interested in the development and exploitation of technology of computerized systems for robotic operation employing software
and artificial intelligence; and

 

WHEREAS,
AVRA desires to expand its capabilities and leading expertise in robot technology in the area of therapeutic, diagnostic and preventative
medicine; and

 

WHEREAS,
IM and AVRA both desire to engage in a collaborative research program with the goals of advancing technical knowledge and patient
care by providing effective robotic medical treatment to patients using software or artificial intelligence systems to be developed
under this Agreement; and

 

WHEREAS,
AVRA has a laboratory and robotic and other equipment, as well as associated knowhow and technology, and IM desires to make use
of AVRA’s laboratory, equipment and information to develop technology; and

 

WHEREAS,
the activities contemplated by this Agreement will be of mutual interest and benefit to IM and AVRA, and for the Parties wish
to enter into this Agreement to provide for the terms and conditions on and subject to which they will conduct collaborative research
and development in the area of robotics, software for robotic operation, and artificial intelligence.

 

AGREEMENT

 

NOW
THEREFORE, in consideration of the mutual premises and covenants set forth herein and intending to be legally bound the Parties
hereby agree as follows:

 

1.
Recitals; Scope and Aims

 

1.1 The
above Recitals are true and correct and are incorporated in this Agreement in their entirety.

 

1.2 This
Agreement governs work performed in a collaborative research and development project between the Parties, which project may include
software development, hardware development, work in the area of artificial intelligence, and discovery or development of medical
knowledge by either or both of the Parties. It is desired by the Parties that IM, with the use of AVRA facilities and the cooperation
of AVRA personnel, will use its commercially reasonable efforts to develop software and/or artificial intelligence systems for
robots that will be relevant to the field of medical treatment or diagnostics, and that IM will grant AVRA exclusive rights to
commercialize any technology developed by IM during the Term (as hereinafter defined) in the field of medical robotics.

 

2. Certain Definitions

 

In
addition to capitalized terms defined elsewhere in this Agreement, following capitalized terms shall have the following meanings,
unless the context otherwise requires:

 

2.1
“Affiliate” means with respect to an entity, any entity that directly or indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with such entity. “Control” and, with
correlative meanings, the terms “controlled by” and “under common control with” mean (a) the power to
direct the management or policies of an entity, whether through ownership of voting securities or by contract relating to
voting rights or corporate governance, resolution, regulation or otherwise, or (b) to own 50% or more of the outstanding
voting securities or other ownership interest of such entity. “Entity” means an individual, sole proprietorship,
partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government
or political subdivision, department or agency of a government

 

    1 | P a g e

     

    

 

2.2
“Existing Technology” means any and all Technical Developments that exists as of the Effective Date of
this Agreement.

 

2.3
“Intellectual Property” means any Patent, trademark (whether registered or not), copyright (whether
registered or not), trade secret or knowhow.

 

2.4
“Patent” means any patent, certificate of invention, inventors certificate, utility model or similar
forms of protection, or other form of protection, including provisional applications, non-provisional utility applications,
design applications, and divisional, continuation, continuation-in-part, and substitution applications based thereon; all
foreign patent applications corresponding to the foregoing applications or directly or indirectly claiming priority to or
from any of the foregoing applications; and all U.S. and foreign patents granted on any of the foregoing applications,
including any extensions, reissues, and reexaminations thereof, granted anywhere in the world covering an invention that is a
Technical Development.

 

2.5
“Party” means IM or AVRA and “Parties” means IM and AVRA collectively.

 

2.6
“Technical Development” means any invention, discovery, composition, creation, enhancement, technology,
advancement, know-how, process, device, article, machine, material, software, system or any other information, including any
development protectable by patent, copyright, or other protection under the law.

 

3.
Term

 

This
Agreement shall have an initial term of five (5) years commencing on the Effective Date, unless earlier terminated in accordance
with the provisions of Section 11 (the “Initial Term”), and shall automatically renew for successive
five (5) year terms (each, a “Renewal Term”), unless terminated by either Party upon not less than one hundred
eighty (180) days written notice given prior to the expiration of the Initial Term or any Renewal Term, or unless earlier terminated
in accordance with the provisions of Section 12. The Initial Term together with any Renewal Term or Renewal Terms shall
be referred to herein as the “Term.”

 

4. Resources

 

4.1 AVRA
will provide to IM full access to the facilities of AVRA, and to the equipment and materials therein, including but not limited
to AVRA’s computer systems and any and all robots or robotic systems or components thereof in AVRA’s control, provided
that providing said access to those facilities or that equipment or material is not unreasonably burdensome to AVRA.

 

4.2 AVRA
personnel will also cooperate with and provide assistance to IM, within reasonable limits that are not unduly burdensome to AVRA.

 

4.3 Each
Party will each bear any costs, expenses, or other charges of whatever nature incurred by such Party in the furtherance of the
joint activities conducted under this Agreement, unless expressly detailed otherwise in this Agreement.

 

5. Intellectual
Property Ownership and Patents

 

5.1 All
rights, title and interest in and to any Existing Technology of IM or of AVRA, respectively, and any Intellectual Property relating
thereto, shall be the exclusive property of the respective Party owning the Existing Technology at the Effective Date.

 

    2 | P a g e

     

    

 

5.2 All
rights title and interest in and to any Technical Development developed by the Parties during the Term and any Intellectual Property
relating in any way thereto, shall be determined according to the origin of the Technical Development, and, in case of inventions,
by inventorship (as defined under U.S. patent law at the time the invention is made), subject to the following:

 

5.2.1 A
Technical Development, and any Intellectual Property relating in any way thereto, shall belong to IM, if the inventor or inventors
are one or more employees of IM or of one or more third parties that have an obligation to assign their rights to IM and none
of the inventors are employees of AVRA (an “IM Invention”).

 

5.2.2 A
Technical Development, and any Intellectual Property relating in any way thereto, shall belong to AVRA, if the inventor or inventors
are one or more employees of AVRA or one or more third parties with an obligation to assign their rights to AVRA and none of the
inventors are employees of IM (an “AVRA Invention”).

 

5.2.3 A
Technical Development, and any Intellectual Property relating in any way thereto, shall belong jointly 50/50 to IM and AVRA if
the inventors include one or more employees of IM or one or more third parties with an obligation to assign their rights to IM
and one or more employees of AVRA or one or more third parties with an obligation to assign their rights to AVRA (herein a "Joint
Invention").

 

5.3 During
the Term, IM and AVRA will each disclose to the other Party all inventions developed, discovered or otherwise made under this
Agreement promptly after becoming aware of such inventions.

 

6. Patents
on IM and AVRA Inventions

 

6.1 IM
shall have the right, but not the obligation, to file Patent applications covering any IM Invention. IM shall be solely responsible
for the prosecution and maintenance of all Patents claiming IM Inventions and all costs related thereto.

 

6.2 AVRA
shall have the right, but not the obligation, to file Patent applications covering any AVRA Invention. AVRA shall be solely responsible
for the prosecution and maintenance of all Patents claiming AVRA Inventions and all costs related thereto.

 

6.3 Each
Party shall give the other Party written notice of its intent to file any such Patent applications at least forty-five (45) days
in advance of the intended filing date, and the other Party shall have the right, but not the obligation to review all Patent
applications and provide the other Party with substantive comments.

 

6.4 Where
a Party determines that it will not submit a Patent application in any country, the other Party may request that the Party submit
that Patent application in specified countries, and the requesting Party shall then reimburse the filing Party for all costs of
filing, prosecuting, responding to opposition (including interference proceedings), and maintaining the Patent application or
resulting Patent in the countries where the Party requested or agreed that Patents should be filed, prosecuted and maintained.

 

6.5 Each
Party shall provide to the other Party a yearly update on the status of all such Patents and Patent applications. Each Party will
provide to the other Party fifteen (15) days’ advance written notice of any deadline for taking action should the Party
have decided to otherwise allow a Patent to go abandoned, and the other Party will have the right to continue prosecution of such
Patent at the other Party’s sole expense.

 

7. Patents
on Joint Inventions

 

7.1 IM
shall have the right to file a Patent application covering any Joint Invention using IM’s Patent counsel of choice. IM shall
give AVRA notice of its intent to file any Patent application covering any Joint Invention at least sixty (60) days in advance
of its filing date. AVRA shall have the right, but not an obligation, to review all Patent applications on Joint Inventions and
to provide IM with substantive comments if AVRA so wishes.

 

7.2 IM
will provide to AVRA forty-five (45) days’ advance written notification of any deadline for taking action with respect to
any Patent for any Joint Invention, should IM decide to otherwise allow the Patent to go abandoned, and AVRA will then have an
option to continue prosecution of such Patent at AVRA’s sole expense. Subject to the preceding sentence IM shall be solely
responsible for filing, prosecuting, responding to oppositions (including interference proceedings) and maintaining all Patents
claiming Joint Inventions and all costs related thereto.

 

7.3 IM
shall consult with AVRA regarding the countries in which patent applications claiming any Joint Invention should be filed, and
IM will file applications in those additional countries where AMC requests IM to do so. IM, at its option and at its expense,
may initially select the list of countries in which to file, and may file in countries where AVRA does not request that IM file
such applications for Patents.

 

    3 | P a g e

     

    

 

7.4 AVRA
shall reimburse IM for all costs of filing, prosecuting, responding to opposition (including interference proceedings), and maintaining
Patents on Joint Inventions filed in additional countries where AVRA requests that applications for Patents be filed, prosecuted
and maintained. AVRA may also, upon sixty(60) days written notice, request that IM discontinue filing, prosecuting, responding
to oppositions, or maintaining Patents or applications for Patents in any such country and, upon expiration of such sixty (60)
day period, may discontinue reimbursing IM for the costs of filing, prosecuting, responding to opposition or maintaining such
Patent application or Patent in any country. Subject to the foregoing, IM will be free to continue, at its own expense at the
end of such sixty (60) day period, to file, prosecute, respond to opposition and/or maintain such Patent application or Patent.

 

7.5 Each
Party undertakes on behalf of itself, its directors, officers, employees, Affiliates and permitted subcontractors to do such further
acts and execute such documents as may be reasonably necessary to give effect to each Party’s rights under this Section
7.

 

8. Licenses

 

8.1 License
to AVRA

 

8.11 IM
hereby grants, and agrees to grant, to AVRA an exclusive, world-wide, perpetual, royalty-free, fully paid-up, perpetual and irrevocable
license to commercialize and exploit in any manner, in the Field of Use (a) all Existing Technology of IM and all Intellectual
Property relating in any way thereto; (b) any IM Invention discovered, created or made in any way during the Term and any Intellectual
Property relating in any way thereto; and (c) all Technical Developments, and all Intellectual Property relating in any way thereto,
which Technical Developments are discovered, created or otherwise made by IM or any of its personnel during the Term. For purposes
of this Agreement, “Field of Use” means the field of Medical Robotics and “Medical Robotics”
means any development, commercialization, manufacture, programming, integration or use of a robot that is configured so that it
may interact with a living person to perform on that person a procedure that includes therapeutic, diagnostic, dermatological,
cosmetic, preventative or any other medical treatment of that person.

 

8.1.2IM
shall retain all rights to the Existing Technology and the Technical Developments discovered, created or otherwise made by IM
or any of its personnel during the Term and any Intellectual Property relating in any way thereto; provided that it shall commercialize
and exploit the foregoing in fields solely outside the Field of Use.

 

8.2 License
to IM

 

AVRA
hereby grants, and agrees to grant, to IM a non-exclusive, world-wide, royalty-free, fully-paid up, perpetual and irrevocable
license to commercialize and exploit in any manner, solely outside the Field of Use, any AVRA Invention discovered,
created or made in any way during the Term and any Intellectual Property relating in any way thereto.

 

    4 | P a g e

     

    

 

9. No
Warranties

 

ANY
INFORMATION, RESULTS, MATERIALS, SERVICES, SOURCES, INTELLECTUAL PROPERTY OR OTHER PROPERTY OR RIGHTS GRANTED, GRANTED ACCESS
TO, OR PROVIDED BY EITHER PARTY TO THE OTHER PARTY PURSUANT TO THIS AGREEMENT ARE ON AN “AS IS” BASIS. THE
PARTIES MAKE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, AS TO ANY MATTER INCLUDING, BUT NOT LIMITED TO, WARRANTY
OF FITNESS FOR PARTICULAR PURPOSE, MERCHANTABILITY, EXCLUSIVITY, ACCURACY, INTEGRATION, OR RESULTS OBTAINED FROM INTELLECTUAL
PROPERTY, INCLUDING BUT NOT LIMITED TO, ANY USE OF ANY INTELLECTUAL PROPERTY MADE OR CREATED UNDER THE AGREEMENT, NOR SHALL ANY
PARTY BE LIABLE TO THE OTHER PARTY FOR INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS
OR INABILITY TO USE, USE PROPERLY, OR USE WITHOUT ERRORS, SAID INTELLECTUAL PROPERTY OR ANY APPLICATIONS AND DERIVATIONS THEREOF.
THE PARTIES MAKE NO WARRANTIES OF ANY KIND WITH RESPECT TO FREEDOM FROM PATENT, TRADEMARK, OR COPYRIGHT INFRINGEMENT, INFORMATIONAL
CONTENT, ACCURACY, INTEGRATION, OR THEFT OF TRADE SECRETS AND BOTH OF THE PARTIES DO NOT ASSUME ANY LIABILITY HEREUNDER FOR ANY
INFRINGEMENT OF ANY PATENT, TRADEMARK, OR COPYRIGHT ARISING FROM THE USE OF THE INTELLECTUAL PROPERTY OR RIGHTS GRANTED OR PROVIDED
BY EITHER PARTY HEREUNDER. THE PARTIES AGREES THAT NEITHER WILL MAKE ANY WARRANTY ON BEHALF OF THE OTHER PARTY EXPRESSED OR IMPLIED,
TO ANY ENTITY CONCERNING THE APPLICATION OF, ACCURACY OF, OR THE RESULTS TO BE OBTAINED WITH THE INTELLECTUAL PROPERTY LICENSED
OR DEVELOPED UNDER THIS AGREEMENT, OR WITH RESPECT TO ANY OTHER MATTER.

 

10. Confidentiality

 

10.1 A
Party receiving Confidential Information (the “Receiving Party”) of the other Party (the “Disclosing
Party”) agrees to maintain the Disclosing Party’s Confidential Information with at least the same degree of care
it holds its own information and in any case not less than a reasonable degree of care.

 

10
2 “Confidential Information” means, with respect to each Party any and all information or material
including any documents, notes, analyses, studies, samples, drawings, flowcharts, databases, models, plans and software
(including source and object codes), other than Exempt Information (as hereinafter defined) in any form which the Disclosing
Party or its Affiliates discloses to the Receiving Party or its Affiliates pursuant to this Agreement, either marked
“Confidential” or, if oral, declared to be confidential when disclosed and confirmed in writing within
thirty (30) days of disclosure. The terms and conditions of this Agreement shall be considered Confidential Information of
both Parties.

 

10.3 For
purposes of this Agreement, “Exempt Information” means information that: (a) the Receiving Party or any of
its Affiliates possessed before the Disclosing Party or its Affiliates disclosed it under this Agreement; (b) is or becomes publicly
known (other than as a result of breach of this Agreement by the Receiving Party or its Representatives); (c) the Receiving Party
or any of its Affiliates obtains from a third party free of any confidentiality obligation to the Disclosing Party or its Affiliates
with respect to such information; or (d) is independently developed by or on behalf of the Receiving Party or its Affiliates without
the use of the Confidential Information.

 

10.4 The
Receiving Party will not use the Disclosing Party’s Confidential Information except as permitted by the Disclosing Party,
or to practice its rights or the activities contemplated under this Agreement. The Receiving Party may disclose the Disclosing
Party’s Confidential Information only to its officers, employees and any permitted agents and advisors concerned with the
conduct of work under this Agreement but will neither disclose the Confidential Information to any third party nor use the Confidential
Information for any other purpose without permission of the Disclosing Party.

 

10.5 Other
provisions of this Section 10 notwithstanding, a Receiving Party may disclose to third parties Confidential Information
of the Disclosing Party as required by law or regulation, provided that the Receiving Party provides reasonable advance written
notice to the Disclosing Party of such third party disclosure so that the Disclosing Party may seek a protective order or other
remedy. If the Disclosing Party fails to obtain a protective order or waives compliance with the relevant provisions of the Agreement,
the Receiving Party will disclose only that portion of the Confidential Information that its legal counsel determines it is required
to disclose.

 

10.6 All
obligations relating to the non-disclosure of Confidential Information shall expire eight (8) years from the end of the Term of
this Agreement.

 

    5 | P a g e

     

    

 

10.7 A
Party will treat as Confidential Information any Technical Development that is owned by the other Party or jointly with the other
Party.

 

10.8 On
expiration or earlier termination of this Agreement, the Receiving Party will, at the written request of the Disclosing Party,
return or destroy (at the Disclosing Party’s sole discretion) all Confidential Information of the Disclosing Party (except
raw data and summary data) then in its possession or control and all copies of it save that the Receiving Party:

 

10.8.1 may
retain a single copy of the Disclosing Party’s Confidential Information for the sole purpose of ascertaining its ongoing
rights and responsibilities in respect of such information; and

 

10.8.2 will
not be required to surrender or destroy any computer files stored securely by the Receiving Party, its Affiliates and permitted
sub-contractors that are created during automatic system back-up or retained for legal purposes by the legal division of the Receiving
Party and its Affiliates.

 

11. Termination

 

Either
Party may terminate this Agreement:

 

11.1 if
the other Party commits a material breach of a material term of this Agreement which, if capable of remedy, remains unremedied
by the breaching Party for sixty (60) days following written requirement by the non-breaching Party to the breaching Party to
cure the same; or

 

11.2 if
the other Party becomes insolvent, the subject of bankruptcy proceedings, enters into an arrangement with its creditors, or any
circumstance analogous to the foregoing; or

 

11.3 at
will and for any reason upon delivery to the other Party sixty (60) days advance written notice of such termination.

 

12. Effect
of Termination

 

12.1 If
this Agreement is terminated by either Party under Section 11, then:

 

12.1.1any
license granted, or agreed to be granted, to AVRA under Section 3.1 shall continue uninterrupted in perpetuity for any
and all Technical Developments, and any Intellectual Property related in any way thereto, made through the date of termination;
and

 

12.1.2any
license granted, or agreed to be granted, to IM under Section 3.2 shall continue uninterrupted in perpetuity for any and
all Technical Developments, and any Intellectual Property related in any way thereto, made through the date of termination.

 

12.2 Sections
5, 6 and 10 shall survive the expiration or termination for any reason of this Agreement.

 

13. Representations
and Warranties

 

13.1 Each
Party warrants that the activities conducted by such Party under this Agreement shall conform to the specifications and the current
material applicable standards, laws, regulations, recognized ethical standards, and procedures of the appropriate U.S. and foreign
regulatory and oversight agencies.

 

13.2 Each
Party represents that it has the right, authority and necessary licenses to enter into and perform its obligations under this
Agreement in accordance with all applicable governmental laws, rules and regulations.

 

    6 | P a g e

     

    

 

14. General
Provisions

 

14.1 Notices
to be given under this Agreement shall be in writing and sent to the Parties by hand delivery or recognized overnight courier
at the following addresses:

 

	 	If
    to IM, to:	Ms. Ruthi Pollak
	 	 	Infinite
                                         Mind LLC

3259
Progress Drive, Suite 107

Orlando,
Florida 32826

	 	 	 
	 	If to AVRA,
    to:	Mr. Barry Cohen, CEO
	 	 	Avra
                                         Medical Robotics, Inc.

3259
Progress Drive, Suite 114

Orlando,
Florida 32826

  

or
to such other address as a Party may designate during the Term by written notice to the other Party. Notices shall be deemed given
upon receipt.

 

14.2 This
Agreement may be executed in one or more counterparts (including by facsimile, ,PDF or other electronic transmission), each of
which shall be deemed an original, and both of which together shall constitute one and the same instrument.

 

14.3 No
waiver is made or given unless in writing and signed on behalf of the Party making such waiver. Any waiver granted on one occasion
shall not be deemed a waiver given on any other or subsequent occasion. All rights of the Parties are cumulative.

 

14.4 Neither
Party may assign this Agreement in whole or in part without the prior written consent of the other Party, save that either Party
may make such assignment to any Affiliate or may make such assignment in the event of any acquisition, merger, or other valid
business reconstruction of such company or business without such consent of the other Party.

 

14.5 This
Agreement constitutes the entire agreement and understanding between the Parties in respect of the subject matter hereof and replaces
in its entirety any prior discussions, negotiations, agreements or other arrangements in relation to the subject matter, whether
written or oral, all of which are replaced by the terms of this Agreement. No amendment or modification of this Agreement shall
be valid or binding unless made in writing and signed by authorized representatives of both parties.

 

14.6 When
possible, each provision of this Agreement will be interpreted in such manner as to be effective, valid, and enforceable under
applicable law, but if any provision of this Agreement is held to be invalid or unenforceable under applicable law, such provision
will be held invalid or unenforceable without invalidating the remainder of such provision or of this Agreement. The Parties will
make a good faith effort to replace the invalid or unenforceable provision with a valid one, which in its economic effect is most
consistent with the invalid or unenforceable provision.

 

14.7 This
Agreement shall be governed in all respects by the laws of the State of Florida, excluding conflicts of law principals. Jurisdiction
and venue for any action brought by a Party to interpret, enforce or otherwise arising under this Agreement shall be brought in
a federal or state court in Orange County, Florida. The prevailing Party in any action brought to interpret, enforce or otherwise
arising under this Agreement shall be entitled to recover attorney’s fees and costs from the non-prevailing party at both
the trial and appellate levels.

 

    7 | P a g e

     

    

 

IN
WITNESS WHEREOF the Parties have caused this Agreement to be executed by the hands of their duly appointed representatives
on the day and date first written above.

 

	INFINITE
    MIND LLC	 
	 	 	 
	By:	/s/
    Ruthi Pollak	 
	 	Ruthi
    Pollak, Manager	 
	 	 	 
	AVRA
    MEDICAL ROBOTICS, INC.	 
	 	 	 
	By:	/s/
    Peter Carnegie	 
	 	Peter
    Carnegie, Director	 

 

 

8
| P a g e

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]